OncoMatch/Clinical Trials/NCT06978699
A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Is NCT06978699 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies XH-S003 Capsule for pnh - paroxysmal nocturnal hemoglobinuria.
Treatment: XH-S003 Capsule — This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: complement inhibitor
Patients who have not previously received any complement inhibitor therapy
Lab requirements
Blood counts
reticulocyte count <100×10^9/l, platelet count <30×10^9/l, or neutrophil count <0.5×10^9/l [excluded]
Liver function
alt, ggt, or alp >3×uln at screening [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify